AstraZeneca's Ultomiris reduces episode occurrence in NMOSD, meeting primary and secondary endpoints
In the rare disease NMOSD (neuromyelitis optica spectrum disorder), patients have attacks or relapses that may cause new onset of a range of symptoms or worsening of symptoms, but a Big Pharma drug might now be able to reduce those episodes.
AstraZeneca, through its rare disease group Alexion, revealed data from the Phase III open-label CHAMPION-NMOSD trial Thursday morning. In May, AstraZeneca had reported the primary endpoint, which was time to first relapse, had been met in the trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
